SkyePharma (SKP)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | n/a |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | n/a |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | |||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, SkyePharma PLC revenues decreased 10% to L49.9M. Net loss before extraordinary items increased from L1.6M to L10.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Exceptional charges increase from L0K to L15.4M (expense), Restructuring Costs provision increase from L0K to L500K (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
SkyePharma PLC is a speciality drug delivery company developing oral and inhalation products. The principal activities of the Company included the research and development, manufacture and sale of prescription pharmaceutical products. The Company is engaged in the development and manufacture of pharmaceutical products based on information used internally by management to assess the performance of, and allocate resources to the business. The Company’s Geomatrix and Geoclock technologies enable controlled- or timed-release versions of immediate-release products to be developed providing advantages to both partner companies and patients. There are 12 approved products in the areas of oral, inhalation and topical delivery, which incorporate the Company’s technologies. The Company’s subsidiaries include SkyePharma Production SAS, SkyePharma (Jersey) Limited, Jago Holding AG, Jagotec AG, SkyePharma AG, SkyePharma Holding AG and SkyePharma Holding Inc.
Directors: Peter Grant (CEO) 56, John Murphy (Counsel) 58,
No. of Employees: 158 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 46,127,645 |
| Free Float | 43.9m (95.1%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Fledgling , FTSE Fledgling XIT, FTSE Techmark Focus , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | 46-48 Grosvenor Gardens, LONDON, SW1W 0EB, United Kingdom |
| Web | http://www.skyepharma.com |
| Phone | +44 20 78810524 |
| Contact | John Murphy (Secy.) |
| Registrar | Capita Registrars |
| Auditors | Ernst & Young LLP |
| 14th May | Holding(s) in Company |
| 13th May | BREO ELLIPTA Receives Regulatory Approval in U.S. |
| 9th May | Result of AGM |
| 9th May | Interim Management Statement |
| 3rd May | Director/PDMR Shareholding |
| 11th Apr | Annual Financial Report |
Recent ↓
